Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...

No. 49 / 2024 Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial ...

Zealand Pharma A/S ( (ZLDPF) ) has released its Q3 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

Boehringer Ingelheim has signed a multi-target collaboration ... and an SSAO/VAP-1-targeting drug from Pharmaxis. Its in-house pipeline in NASH is led by survodutide (BI 456906), a glucagon ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

It covers the pipeline drug profiles, including clinical and nonclinical ... of LYT-100 in patients with IPF in the first ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...